Sixty Degree Capital

Our expertise in biopharma and biotech investments. With decades of experience and a robust network within the biopharma and biotech industries, our team offers unparalleled insight into the scientific and financial landscapes. We are dedicated to identifying transformative therapies and supporting companies that are pioneering the future of healthcare. Empowering entrepeneurs to build leading companies Biovance Capital works closely with entrepreneurs to build leading companies with transformative treatments for patients in need. Stage: We invest in early-stage companies at seed and Series A rounds across Europe, with a focus in Southern countries. Technology: We invest in biotech companies developing therapeutics in any modality and therapeutic area. We require robust and appropriate preclinical models and patented or patentable assets before investing. Market: Large target market with a clear regulatory pathway for approval, with favorable reimbursement and pricing policies. Exit Potential: Sectors with VC/M&A or IPO activity, featuring profitable exits and multiple potential acquirers. Sustainability: During the due diligence process, sustainability risks are taken into account, and whenever identified, mitigation measures are proposed.

We are inspired by a vision for the future in which data, computing, networks, and other digital and deep technologies deliver meaningful outcomes and insight for improving health and the provision of care. We invest in both solutions intended for use in the diagnosis or cure of disease and solutions designed to help healthcare organizations - be them hospitals, biopharmas, insurers, etc. - be better at what they do. We see our sweet spot at seeding founders who are marrying in-depth understanding of the complex network of healthcare system participants with meaningful engineering innovation, advanced data science, and information technology-enabled products and services. We look for and invest in founders determined to effectively and efficiently serve these participants on the european continent, where we are based, and internationally.​ In our investment criteria and process, we are informed by a Stanford-born methodology of health technology innovation known as Biodesign. Since 2001, Biodesign has proven to de-risk the process of new venture creation by applying a need-driven and value-based approach to reinventing healthcare with the help of technology. To learn more about the methodology, head to The Student Guide to Biodesign, developed by a team of Stanford instructors and students who are passionate about education and making high-quality learning materials available and accessible to all.​ We invest in european companies as well as in selected non-european companies with ties to europe. Wherever they are, our goal is to help founders ready their companies to raise series A capital, and to access international markets. To learn more about our process, click here.

We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage - from founders and the investors that back them. What we look for We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential. Our approach Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure. Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract. Release the required funding, close the transaction and work together to grow the business.

At StartUp Health, we are impact-driven entrepreneurs and investors building a global army of thousands of Health Transformers collaborating to achieve health moonshots --- from ending cancer and curing disease, like diabetes and Alzheimer’s, to delivering quality care to everyone in the world regardless of location or income. We believe that investing in and supporting a diversified global portfolio of health moonshot companies is the key to improving the health and wellbeing of humanity, while also generating healthy financial returns for investors. Since 2012, we’ve made more than 400 investments in companies across 27 countries, and currently have a portfolio of 260+ active companies. We have a flexible, work-from-anywhere policy as our team is fully remote, with team members in NYC, San Francisco, Los Angeles, Baltimore, and Philadelphia. We are open to candidates across the U.S. Benefits include health insurance and long-term disability coverage, 401k with employer matching, employee stock options, and generous time off policy including paid holidays.

At Pappas Capital, we are dedicated to furthering life science discoveries and bringing groundbreaking solutions to market. Pappas Capital is laser focused on the life science sector. For more than 28 years we have been investing in and building innovative companies that are developing the next generation of life science products and technologies. We’ve invested in more than 85 companies across the United States and Canada – in fields that span the range of human disease. The products our companies have brought to market – for treating such conditions as melanoma, ovarian cancer, and hemophilia, to name a few – have been used throughout the world to treat tens of thousands of patients and account for billions of dollars of revenue. Whether you’re looking for capital or have capital to invest, contact us and learn how we can put our expertise to work for you.

Trinity Innovation Bioventure Singapore is a licensed biomed venture capital fund focusing on innovation and value investment with deep insight and experience on Asia markets. We are part of the Trinity Innovation Fund group, founded in 2018, managing multiple VC funds in the region. We are an experienced team led by industrial veterans who have managed multiple VC funds and invested over dozens of biotech companies. Our StrengthAccess to China market through synergy with TIF: Two organizations, One Team Multi-dimensional value-added post investment to enhance possibility of success and returns Clear investment thesis: In Asia, for Global; Leverage regional synergy and realize future value Best-in-class team in biomed investment with strong track record Our Focus TIBS seeks to invest and build great companies that emerging biotechnology leads to innovative therapeutics to address global unmet medical needs. We focus on incubating and growing potential early-stage biotech start-ups with breakthrough platform technology, differentiated scientific merit and commercial value. Our Core CompetencyValue Discovery: Select investment projects based on precise judgements from in-depth research Project Incubation: Incubate cutting-edge science or outstanding entrepreneurs with innovative approaches. Unique incubation strategy: project management by investment team to increase the asset value; management team recruitment to maximize the equity value and capital efficiency Help entrepreneurs to grow rapidly with proprietary foresight, industry understanding and resources